Low-Cost and Readily Available Tissue Carriers for the Boston Keratoprosthesis: A Review of Possibilities

Journal of Ophthalmology (Impact Factor: 1.43). 11/2013; 2013(6):686587. DOI: 10.1155/2013/686587
Source: PubMed


The Boston keratoprosthesis (B-KPro), currently the most commonly used artificial cornea worldwide, can provide rapid visual rehabilitation for eyes with severe corneal opacities not suitable for standard corneal transplantation. However, the B-KPro presently needs a corneal graft as a tissue carrier. Although corneal allograft tissue is readily available in the United States and other developed countries with established eye banks, the worldwide need vastly exceeds supply. Therefore, a simple, safe, and inexpensive alternative to corneal allografts is desirable for the developing world. We are currently exploring reasonable alternative options such as corneal autografts, xenografts, noncorneal autologous tissues, and laboratory-made tissue constructs, as well as modifications to corneal allografts, such as deep-freezing, glycerol-dehydration, gamma irradiation, and cross-linking. These alternative tissue carriers for the B-KPro are discussed with special regard to safety, practicality, and cost for the developing world.

Download full-text


Available from: Roberto Pineda, Feb 12, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Artificial corneas are being developed to meet a shortage of donor corneas and to address cases in which allografting is contraindicated. A range of artificial corneas has been developed. Here we review several newer designs and especially those inspired by naturally occurring biomaterials found with the human body and elsewhere. Recent trends in the development of artificial corneas indicate a move towards the use of materials derived from native sources including decellularized corneal tissue and tissue substitutes synthesized by corneal cells in vitro when grown either on their own or in conjunction with novel protein-based scaffolds. Biologically inspired materials are also being considered for implantation on their own with the view to promoting endogenous corneal tissue. More recent attempts at making artificial corneas have taken a more nature-based or nature-inspired approach. Several will in the near future be likely to be available clinically.
    Current opinion in ophthalmology 03/2014; 25(3). DOI:10.1097/ICU.0000000000000049 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of this study was to develop a modified ex vivo corneal cross-linking method that increases stromal resistance to enzymatic degradation for use as a carrier for the Boston keratoprosthesis. Methods: Ex vivo cross-linking of human corneas was performed using Barron artificial anterior chambers. The corneas were deepithelialized, pretreated with riboflavin solution (0.1% riboflavin/20% dextran), and irradiated with ultraviolet A (UV-A) light (λ = 370 nm, irradiance = 3 mW/cm) for various durations. The combined effect of UV-A and gamma (γ) irradiation was also assessed using the commercially available γ-irradiated corneal donors. The corneas were then trephined and incubated at 37°C with 0.3% collagenase A solution. The time to dissolution of each cornea was compared across treatments. Results: Deepithelialized corneas (no UV light, no riboflavin) dissolved in 5.8 ± 0.6 hours. Cross-linked corneas demonstrated increased resistance to dissolution, with a time to dissolution of 17.8 ± 2.6 hours (P < 0.0001). The corneal tissues' resistance to collagenase increased with longer UV-A exposure, reaching a plateau at 30 minutes. Cross-linking both the anterior and posterior corneas did not provide added resistance when compared with cross-linking the anterior corneas only (P > 0.05). γ-irradiated corneas dissolved as readily as deepithelialized controls regardless of whether they were further cross-linked (5.6 ± 1.2 hours) or not (6.1 ± 0.6 hours) (P = 0.43). Conclusions: Collagen cross-linking of the deepithelialized anterior corneal surface for 30 minutes conferred optimal resistance to in vitro keratolysis by collagenase A.
    Cornea 07/2014; 33(9). DOI:10.1097/ICO.0000000000000185 · 2.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: “Artificial corneas” have been attempted in severe corneal disease for at least 230 years, with largely disappointing results until recently. ‘The Boston Keratoprosthesis’ (B-Kpro) has been part of this history on and off for a half century. Developed from several previously known concepts, it was originally made of PMMA plastics in a collar button design (Type I), to be implanted into a corneal graft carrier and then transplanted to the patients’ cornea. (A Type II with an additional stem for lid penetration is occasionally used in end-stage dry eyes.)Management and device changes have over the years led to marked clinical improvements. Thus, postoperative infections have been drastically reduced by using low-dose prophylactic antibiotics. The corneal surface has been found to be well protected from evaporative damage by a soft contact lens or a conjunctional flap. Postoperative tissue melt around the device has been markedly reduced by improvement of nutrition from the aqueous (perforated back plates) and better anti-inflammatory strategies. Titanium alloys can be used for non-transparent parts to reduce inflammation and increase biointegration. Retroprosthesis membranes and retina complications have similarly been markedly reduced. However, post-operative glaucoma is still a stubborn problem that can cause long-term attrition of vision. Autoimmune diseases are particularly treacherous and B-KPros should not at present be used routinely. About 12,000 Boston Keratoprostheses have so far been distributed world-wide. Robust research is presently on-going to improve long-term safety, especially for the developing world.
    Spektrum der Augenheilkunde 01/2015; 28(6). DOI:10.1007/s00717-014-0240-7 · 0.18 Impact Factor
Show more